Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 9, 2026, 9:20 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: SYNERGY Clear all
Completed Not applicable Interventional

Clinical Outcomes Following Implantation of Tecnis Synergy and Symfony Intraocular Lens

NCT05541796
View directory record Official record
Conditions
Cataract
Interventions
Intraocular lens
Device
Lead sponsor
George O. Waring IV
Other
Eligibility
40 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Mt. Pleasant, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 22, 2024 · Synced Sep 9, 2026, 9:20 AM EDT
Completed Phase 2 Interventional Results available

Phase II Gemcitabine + Fractionated Stereotactic Radiotherapy for Unresectable Pancreatic Adenocarcinoma

NCT01146054
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
CyberKnife based stereotactic radiotherapy, Gemcitabine, Fludeoxyglucose (18F) (FDG)
Device · Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
3
States / cities
Stanford, California • Baltimore, Maryland • New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 18, 2017 · Synced Sep 9, 2026, 9:20 AM EDT
Not listed Phase 4 Interventional

Exercise And Rosuvastatin Treatment: Is There an Anti-Inflammatory Synergy?

NCT00295373
View directory record Official record
Conditions
Nonfamilial Hypercholesterolemia, Physical Inactivity
Interventions
Rosuvastatin, Exercise Training
Drug · Behavioral
Lead sponsor
Purdue University
Other
Eligibility
40 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
West Lafayette, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 19, 2007 · Synced Sep 9, 2026, 9:20 AM EDT
Completed No phase listed Observational

Patient Preference and Visual Quality With Contralateral Synergy Versus Panoptix

NCT05610540
View directory record Official record
Conditions
IOL, Cataract, Patient Satisfaction
Interventions
TECNIS Synergy IOL, AcrySof PanOptix Trifocal IOL
Device
Lead sponsor
Bucci Laser Vision Institute
Other
Eligibility
40 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Wilkes-Barre, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 26, 2023 · Synced Sep 9, 2026, 9:20 AM EDT
Completed Not applicable Interventional Results available

Effects of Device-assisted Practice of ADL on Arm/Hand Recovery in Individuals With Moderate to Severe Stroke

NCT04077073
View directory record Official record
Conditions
Stroke
Interventions
ReIn-Hand, Robot
Device
Lead sponsor
Northwestern University
Other
Eligibility
21 Years to 80 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced Sep 9, 2026, 9:20 AM EDT
Completed Phase 3 Interventional Results available

Open-label Extension (OLE) Study of Plecanatide for Chronic Idiopathic Constipation (CIC)

NCT01919697
View directory record Official record
Conditions
Chronic Idiopathic Constipation
Interventions
Plecanatide
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 81 Years
Enrollment
2,370 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
211
States / cities
Birmingham, Alabama • Dothan, Alabama • Gulf Shores, Alabama + 160 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2019 · Synced Sep 9, 2026, 9:20 AM EDT
Not yet recruiting Phase 4 Interventional

Examining Analgesic Synergy and Efficacy in Trauma Care

NCT07435077
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Buprenorphine, Oxycodone
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 80 Years
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 9, 2026, 9:20 AM EDT
Not listed Phase 2 Interventional

Methylphenidate Plus GWI-Nutrient Formula as a Treatment for Patients With Gulf War Illness

NCT02357030
View directory record Official record
Conditions
Gulf War Illness
Interventions
Methyl-P plus GWI Nutrient Formula
Drug
Lead sponsor
K-PAX Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Oct 14, 2015 · Synced Sep 9, 2026, 9:20 AM EDT
Not listed Not applicable Interventional

Prospective Evaluation and Comparison of Bilateral Synergy Implants and Bilateral PanOptix Implants

NCT05186298
View directory record Official record
Conditions
Cataract
Interventions
AcrySof® IQ PanOptix®, Synergy®, Cataract Surgery
Device · Procedure
Lead sponsor
Alterman, Modi, & Wolter Ophthalmic Physicians & Surgeons
Other
Eligibility
22 Years and older
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
5
States / cities
Panama City, Florida • Poughkeepsie, New York • Kingston, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2022 · Synced Sep 9, 2026, 9:20 AM EDT
Completed Not applicable Interventional Results available

ABLATE Post Approval Study - Synergy Ablation Lesions for Non-Paroxysmal Atrial Fibrillation

NCT01694563
View directory record Official record
Conditions
Persistent Atrial Fibrillation, Longstanding Persistent Atrial Fibrillation
Interventions
Synergy Ablation System
Device
Lead sponsor
AtriCure, Inc.
Industry
Eligibility
18 Years and older
Enrollment
365 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
49
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 41 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2019 · Synced Sep 9, 2026, 9:20 AM EDT
Completed Phase 2 Interventional Results available

Comparison of A Single Dose Combination of Methadone and Morphine With Morphine Alone for Treating Post-operative Pain

NCT00142519
View directory record Official record
Conditions
Pain
Interventions
Methadone, methadone and morphine
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 14, 2019 · Synced Sep 9, 2026, 9:20 AM EDT
Terminated Phase 1 Interventional

Dasatinib and Cyclosporine in Treating Patients With Chronic Myelogenous Leukemia Refractory or Intolerant to Imatinib Mesylate

NCT01426334
View directory record Official record
Conditions
Accelerated Phase Chronic Myelogenous Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Phase Chronic Myelogenous Leukemia, Relapsing Chronic Myelogenous Leukemia
Interventions
dasatinib, diagnostic laboratory biomarker analysis, pharmacological study, cyclosporine
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
2
States / cities
Aurora, Colorado • Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 1, 2014 · Synced Sep 9, 2026, 9:20 AM EDT
Completed Phase 3 Interventional Results available

AtriCure Bipolar Radiofrequency Ablation of Permanent Atrial Fibrillation

NCT00560885
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
AtriCure Bipolar System
Device
Lead sponsor
AtriCure, Inc.
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
9
States / cities
Sacramento, California • Indianapolis, Indiana • Grand Rapids, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2013 · Synced Sep 9, 2026, 9:20 AM EDT
Enrolling by invitation No phase listed Observational

CorEvitas SPHERES (Synergy of Prospective Health & Experimental Research for Emerging Solutions) Registry for Neuromyelitis Optica Spectrum Disorder (NMOSD)

NCT04886492
View directory record Official record
Conditions
Neuromyelitis Optica Spectrum Disorder
Interventions
Not listed
Lead sponsor
CorEvitas
Network
Eligibility
18 Years and older
Enrollment
800 participants
Timeline
2021 – 2099
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 8, 2026 · Synced Sep 9, 2026, 9:20 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Diet Synergy in Muscle Protein Synthesis

NCT07367854
View directory record Official record
Conditions
Muscle Protein Synthetic Response to Protein, Muscle Protein Synthesis, Muscle Health, Protein Metabolism, Recreational Activities, Isotope Labeling
Interventions
Resistance Exercise, Potato and Beef, Bread and Beef, Beef
Behavioral · Dietary Supplement
Lead sponsor
University of Illinois at Urbana-Champaign
Other
Eligibility
19 Years to 40 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Urbana, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Sep 9, 2026, 9:20 AM EDT
Completed Phase 3 Interventional Results available

A Clinical Trial to Assess the SYNERGY 48 mm Stent System for the Treatment of Atherosclerotic Lesion(s)

NCT03350542
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
SYNERGY 48 mm
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
8
States / cities
Birmingham, Alabama • Saint Paul, Minnesota • New York, New York + 5 more
Source: ClinicalTrials.gov public record
Updated May 13, 2021 · Synced Sep 9, 2026, 9:20 AM EDT
Completed Phase 1 Interventional

Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients

NCT02152943
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Estrogen Receptor Positive, HER2/Neu Positive, Postmenopausal, Premenopausal, Progesterone Receptor Positive, Recurrent Breast Carcinoma, Refractory Breast Carcinoma, Refractory Hormone Receptor Positive Breast Carcinoma, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7
Interventions
Everolimus, Laboratory Biomarker Analysis, Letrozole, Trastuzumab
Drug · Other · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
5
States / cities
Houston, Texas • Nassau Bay, Texas • Sugar Land, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2020 · Synced Sep 9, 2026, 9:20 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Physical Activity Modifies Exercise Responsiveness

NCT07792967
View directory record Official record
Conditions
Multimorbidity
Interventions
SLIMM - Sit less, interact, move more, PB125
Behavioral · Dietary Supplement
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
60 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2027 – 2031
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 9, 2026, 9:20 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Visual Outcomes and Patient Satisfaction With Bilateral PanOptix Verses Bilateral Synergy

NCT06041139
View directory record Official record
Conditions
Pseudophakia
Interventions
Visual Acuity, Defocus Curve, Halo and Glare testing, Patient Questionnaires
Diagnostic Test · Other
Lead sponsor
Berkeley Eye Center
Other
Eligibility
40 Years and older
Enrollment
230 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 22, 2025 · Synced Sep 9, 2026, 9:20 AM EDT
Completed No phase listed Observational Results available

Synergy Lens Outcomes Evaluation

NCT05418153
View directory record Official record
Conditions
Presbyopia, Pseudophakia
Interventions
Tecnis Synergy IOL
Device
Lead sponsor
Center For Sight
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
2
States / cities
Venice, Florida • Mt. Pleasant, South Carolina
Source: ClinicalTrials.gov public record
Updated Mar 17, 2024 · Synced Sep 9, 2026, 9:20 AM EDT
Completed Phase 2 Interventional Results available

Comparing the Efficacy, Safety, and Tolerability of Combination Antivirals (Amantadine, Ribavirin, Oseltamivir) Versus Oseltamivir for the Treatment of Influenza in Adults at Risk for Complications

NCT01227967
View directory record Official record
Conditions
Influenza
Interventions
Amantadine, Ribavirin, Oseltamivir, Oseltamivir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
881 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
69
States / cities
Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 58 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2019 · Synced Sep 9, 2026, 9:20 AM EDT
Completed Phase 1 Interventional Results available

Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor

NCT03239145
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
Pembrolizumab, Trebananib
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Sep 9, 2026, 9:20 AM EDT
Terminated Not applicable Interventional Results available

A Clinical Study Comparing Postoperative Outcomes Between the TECNIS Intraocular Lens.

NCT05396599
View directory record Official record
Conditions
Cataract
Interventions
Model DIU, Model DFW, Model ZCT
Device
Lead sponsor
Johnson & Johnson Surgical Vision, Inc.
Industry
Eligibility
22 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
5
States / cities
Los Angeles, California • Orange, California • San Francisco, California + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2024 · Synced Sep 9, 2026, 9:20 AM EDT
Completed Phase 4 Interventional Results available

EVOLVE Short DAPT Study

NCT02605447
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
3 months of dual antiplatelet therapy (DAPT), SYNERGY Stent System
Drug · Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
2,009 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
89
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Bakersfield, California + 75 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2020 · Synced Sep 9, 2026, 9:20 AM EDT